►
Description
Open project meeting for Open Source Antibiotics Series 1, the Mur Ligases.
Full Project: https://github.com/opensourceantibiotics/murligase
Relevant GitHub Issue: https://github.com/opensourceantibiotics/murligase/issues/43
On the call: Professor Matthew Todd, Dr Dana Klug, Yuhang Wang (UCL), Professor Chris Dowson, Laura Diaz Saez, Rebecca Steventon (University of Warwick), Lizbe Koekemoer, Gustavo Arruda Bezerra (Diamond/Oxford), Bart Staker (SSGCID), Dr Lori Ferrins, Dr Joe Eyermann (NEU), Peter Horanyi (UCB), Dr Chris Swain (Cambridge MedChem Consulting).
A
Okay,
hi
everybody,
tuesday
11th
of
may
and
we're
talking
today
about
the
mural
eye
gazers
and
let
me
share
screen,
so
you
we've
all
got
the
same
thing
in
front
of
us.
That
might
just
be
the
easiest
thing
to
do
right.
A
Is
that
the
right
window?
Hopefully
everyone
can
see
that
okeydoke,
so
I
mean
it
might
just
be
easiest
to
to
whip
through
some
of
the
things
we
spoke
about
last
time,
so
the
actions
from
last
time
which
which
will
probably
bring
up
everything
we
want
to
talk
about.
A
Actually,
so
you
have
been
pursuing
synthesis
of
the
az
compound
that
we
need,
for
you,
know,
maybe
further
study
and
having
some
issues
with
a
with
an
eye
summit
being
made,
and
it's
good
ideas
about
how
to
how
to
be
that
and
has
been
acting
on
some
suggestions
from
from
from
joe
you
ain't.
Do
you
want
to
say
anything?
I
mean
it's
all
in
the
update
you
provided
on
the
on
the
github
post,
which
is
awesome.
Do
you
want
to
say
anything
about
that.
C
Yeah,
okay,
sure,
that's
a
lot
of
pressure,
all
right,
so
for
the
so
this
week
this
month,
I
exported
three
different
temperature
scales
to
trying
to
get
the
get
the
blue
and
the
blue
ideal
product,
which
is
a
typical
interaction
core
for
the
is
a
compound
and
what
I've
been
trying
to
do
is
to
trying
to
use
the
base
in
the
solvent
to
generate
the
methyl
hydrogen
in
situ,
so
that,
like
so
that
I
could
preferably
get
the
get
this
blue
product.
B
A
Yeah
I
mean
yeah,
which
is
the
isomer
and
so
you're,
trying
to
you're
trying
to
prove
that
by
making
this
theory
and
crystallizing
it
bring
it
yeah,
exactly
yeah,
cool
and
and
then
I
think,
you've
been
also
investigating
other
potential
ways
of
yeah.
C
Yeah,
so
I'm
not
quite
sure
about
the
first
line
of
the
next
next
step,
which
is
the
reaction
I've
been
doing.
I
finished
today
the
wya
all
right,
yeah,
this
guy.
This
guy
is
from
joe,
so
I
designed
I
decided
to
do
this
where,
as
soon
as
the
starting
material.
B
C
B
C
I
have
a
actually
I
have
a
question
about
the
reaction.
Could
you
please
scroll
up
a
bit
then
yeah,
so
the
first
reaction,
the
next
step,
so
I
changed
the
solvent
system
I
I
just
saw,
but
this
is
not
public.
This
is
not
referenced.
C
It's
just
the
software
system
taken
from
the
reference,
but
with
different
starting
materials.
So
I'm
not
quite
sure
if
this
will
work
or
not,
but
the
essential
idea
is
to
generate
the
methyl
hydrogen
institute.
That's
what
I
want
to
do
and
I
think
this
condition
is
a
bit
useful
because
the
a
form
solves
and
it
will
get
isolated
from
the
system.
D
Sorry
so
just
a
joke,
so
I
I
guess
I
mean
valiant
efforts
here.
Are
you
know
I?
I
don't
know
you
know?
Obviously
I'm
not
a
synthetic
chemist.
I
can
help
you
on
that
aspect
of
it,
but
you
know
one
of
the
things
I
think
I
mean
I
guess
my
my
recommendation.
I
mean
I'm
not
trying
really
is
to
move
on
to
trying
to
make
the
you
know
the
isopropyl,
the
one
at
the
bottom.
It's
you
know
it's
commercially
available.
D
So
I
don't
remember
what
the
actual
mic
of
the
compound
on
the
right
is
the
isopropyl
version,
but
I
mean
one
of
the
things
here
you
would
get
would
be.
You
know
once
if
you
made
the
amine
of
this
analog
with
the
isopropyl
pyrazole.
D
You
know
in
theory,
you
should
have
even
more
of
we
call
it
a
delta
more
of
a
shift
in
the
actual
mic
to
test
your
hypothesis
that
adding
a
basic
amine
would
actually
improve
the
mic.
D
So
just
from
a
I
don't
know,
I
think,
from
an
efficiency
and
time
point,
I
I'm
not
sure
I
would
pursue
the
top
too
much
more
and
really
kind
of
see
if
you
can
generate
you
know
the
isopropyl
analogs
and
then
move
on
to
trying
to
make
the
you
know
the
amino
version
of
that
I
mean
that
would
be
my
my
recommendation
at
this
point.
A
Yeah,
I
think
we're
we're
caught
here
in
the
usual
tension
between
you
know,
prosecuting
a
medcam
campaign
and
doing
things
which
are
good
for
a
phd.
A
C
A
Great
all
right
thanks,
so,
hopefully
you
know
compounds
will
be
made
by
I
mean
guess
by
the
next
meaning
we
should
be
having
these.
I
think
the
way
the
way
you're
going.
You
hang
and
obviously,
when
we've
got
those
we
can
distribute
them
around
to
anyone
who
wants
them
and
then
we'll
get
on
with
making
analogous
compounds.
But
we
wanted
to
get
you
know.
Ideally,
an
active
and
inactive
and
an
experimental
would
be
great.
So
you
know
this
compound,
plus
something
that's
inactive,
maybe
as
a
control
plus
the
amy.
Definitely
those
are
the
targets.
Yeah.
A
All
right
awesome
thanks
for
that,
and
then
update
on
the
shipping
of
the
atomizers
is
that
we
have
bifurcating
multiplying
paperwork,
so
there's
mtas
now
being
have
been
sent
from
ucl
to
to
warwick
and
diamond
and
those
are
being
investigated
by
those
institutions
before
and
that
would
constitute
an
agreement
which
we
can
then
say
to,
and
then
we
can
set
you
out
and
wise.
We
formed
an
agreement,
everyone's
happy.
A
We
can
go
ahead,
so
the
paperwork
is
at
least
happening
and
it's
being
digested.
A
I
don't
have
much
more
update
to
say
than
that,
nor
the
will
to
talk
about
it
much
more
agreed.
So
so
then,
so
this
this
is
a
moot
now,
because
we're
not
gonna
ship,
directly
diamond
because
diamond
turns
out.
I
think
also
maybe
would
like
well
no.
A
In
the
need
for
ecl
to
have
an
mta,
so
we're
going
to
go
with
that
route.
All
right
next
thing
was
back
as
a
complete
screening
of
let's
actually
see
fragments,
okay,
screening
of
dance
collaborative
fragments.
Do
we
do?
Does
anyone
involved
in
that
want
to
update
us.
E
Yeah,
so
the
screening
of
lisby's,
the
actual
compounds,
are
all
finished,
we're
just
running
a
few
side
tests
to
just
try
and
confirm
if
they
were
binding,
where
we
expected
them
to
dana's
hasn't
started.
That's,
unfortunately,
we've
just
moved
labs,
which
has
caused
us
to
have
to
recheck
all
the
equipment
and
everything,
but
that's
all
up
and
running
all
the
testing's
done
so
equipment's
ready,
everything's
now
ready
to
run
the
testing.
A
Awesome
all
right
so
so
does
that
mean
that
the
the
elizabeth's
fragments
have
been
done?
You've
got
data
on
those
and
then
the
next
thing
to
do
will
be
the
dana
fragments.
E
A
All
right,
awesome,
great,
okay
and
then
laura
didn't
continue.
Crystallization.
D
D
I
understand
I
I
I
I
I
know
that's
not
happening
yet
anyway,
but
these
are
the
ones
I
assume
that
from
the
the
e
screen.
You
know
the
stuff
that
you
know
it's
been
out
and
you
know
like
chris
and
others
have.
You
know
tried
to
do
design
on
it's
those
fragments
right.
E
I
can't
speak
to
who
else
has
been
working
on
them.
I
just
know
that
they're
they
were
targets
against
my
e
binding
to
a
little
side
pocket,
not
any
of
the
substrate
finding
pockets.
D
Right:
okay,
thanks
thanks
thanks
thanks
a
lot.
A
I
mean,
I
guess:
if
we,
if
we
are
able
to
share
the
data
we
can,
we
can
just
confirm
the
identity
yeah
as
well,
and
then
crystallization
trials,
laura
you're,
gonna
you're.
I
remember
the
last
time
you
were
involved
in
all
this
how's
it
going.
G
Yes,
so
I'm
going
to
start
with
me
or
c.
Sorry
me
near
e.
I
I'm
going
to
do
the
fragment
screening
this
friday
in
the
presence
of
magnesium
to
see
if
we
can
get
a
hits
that
are
more
reproducible
from
ud
that
when
the
crystals
are
not
that
reproducible,
so
I'm
trying
to
get
new
conditions
and
start
a
startup
like
the
condition
I
was
following
up
is
not
giving
as
many
crystals
as
I
wanted.
So
I'm
continuing
with
that,
but
at
least
we
have
some
something
going
on
on
friday.
A
A
A
And
again
so
same
question
as
joe
here,
the
these
are
the
same
fragments
or
are
we?
Are
we
testing
the
same.
G
Library
is
the
same
library,
but
the
previews.
The
first
screen
that
was
done
wasn't
done
in
the
presence
of
magnesium.
So
I
incorporate
in
magnesium
and
see
if
that
gives
all
the
type
of
hits
and
like
more
real
hits
that
we
can
reproduce
later
on.
D
Okay,
so
I'm
confused
again
sorry,
I
keep
bugging
into
this
conversation
so
which
first
screen
okay.
So
there
was
an
original
screen
that,
I
think,
is
a
diversity
library
out
of
out
of
the
diamond
yeah,
and
then
there
was
a
second
one,
which
was
actually
the
the
compounds
that
becca
and
I
put
together
the
600
compound
library.
So
I
assume
this
is
the
diamond
diversity,
library
diamond
one
yeah.
So
it's
the
same
one
that
produced
the
original
set
of
fragments
the
list.
The
quote
this
bk
fragment.
A
So,
that's,
that's
all
the
biology!
That's
in
warwick.
Does
anyone
have
any
follow-up
questions
about
this
stuff?
That's
going
on.
A
Okay,
all
good,
and
then
the
next
item
was
joe
chris
and
bart,
pursue
as
a
comment
shipment
for
crystallization
trials
is
that
finished
now?
Have
I
mistakenly
included
that
in
the
actions
no.
I
I
I
forget
when
that
was,
but
maybe
it
was
only
a
couple
weeks
ago
and
that's
the
last
I've
heard
so
in
order
to
for
them
to
so,
it
seems
like
they
were
willing
to.
You
know
to
move
forward.
So
that's
good.
I
F
F
So
I
suppose
I
mean
no
one's
objecting.
I
don't
think
it's
somebody
if
somebody
has
agreed
to
do
it
and
then
it's
been
devolved
to
the
legal
team
and
the
legal
team
do
what
the
legal
team
do,
which
is
clock
up
hours
and
make
money
and
yeah
and
it
needs
to.
There
does
need
to
be
a
way
through
all
all
of
this,
and
even
with
our
own
institutions.
It's
the
same
thing.
I
think
we
really
do
need
platform
agreements,
you
know
and
part
par.
F
D
D
D
Usually
it's
just
a
matter
of
they
have
a
legal
agreement
and
then
it's
really,
you
know
the
the
collaboration
on
on
the
receiving
end
of
who
wants
to
get
access
to
compounds
for
them
to
actually
get
the
thing
through
and
agree
to
you
know
the
terms
and
conditions
of
you
know
astrazeneca's
legal
agreement,
and
how
much
of
that
you
want
to
edit
and
change
then
that
gets
into
you
know
really
more
more
of
the
issue.
So
it's
anyway,
I
just
feel
like
it's
not
usually
it's
not
astrazeneca.
That's
holding
things
up.
D
D
You
know
you
can
grease
the
wheels
that
way
that
that's
how
things
will
get
moved
forward.
In
my
opinion,
unfortunately,.
A
That's
the
frustrating
thing
so
my
argument's
about
the
fact
that
in
this
case
there
is
a
risk
somewhere,
I
mean
there's
a
risk
somewhere
that
one
of
the
atomized
compounds
is,
you
know
explosive
right
and
we
ship
it
and
someone
gets
injured
and
then
ucl
is
liable
right,
there's
a
risk
of
that
it
turns
out.
The
risk
has
several
is
several
places
away
from
the
decimal
point,
but
it
doesn't
matter
right.
It's
still
a
risk,
and
so
the
documents
need
it
and
that's
the
same
amount
of
time
it
takes
if
the
risk
was
very
high.
A
That's
the
frustrating
thing
that
there's
no.
C
F
F
I
Our
legal
department
is
is
also
quite
risk-averse
and
unlikely
to
have
any
incentive
to
do
anything
on
this.
So
I
I
sort
of
like
a
toss-up.
As
far
as
I
know,
I
wish
that
they
would
at
least
tell
us
if
they
had
compounds,
because
they
also
they're
not
going
to
ship
them
if
they
don't
have
them
like
they're,
not
going
to
make
them.
D
This
this
that's
already
cleared
part.
That
was
it
they
had
the
compounds
yeah.
We
went
through
this
whole
process
with
with
with
pam
and
kelly,
I
mean
they
have
the
compounds,
that's
not
the
issue.
We
went
through
the
list,
we
sent
them
a
request
and
they
checked
their
inventory
and
they
have
the
compounds.
So
it's
that's,
not
the
issue.
Really,
it's
it's
in
it's
in
our
court.
If
you
know
if
this
is
going
to
happen,
it
has
to
happen
on
our
end
and
so
yeah.
D
A
I'm
sure
that's
not
going
to
happen
all
right.
J
A
The
the
idea
of
a
of
a
of
a
shared
project
agreement
that
we
sought
out
in
advance
is
a
nice
one
still
in
requires
a
document
and
some
and
some
sharing
of
documents,
but
it
would
at
least
cover
everything
which
is
it,
which
is
a
nice
idea,
maybe
next
time
or
in
in
the
near
future.
We
could
try
that
okay.
A
The
next
item
was
that
me
and
eucharist
were
investigating
the
entrap
funding,
so
I
I'm
still
intending
to
apply
for
that
and
I'm
just
going
to
need
your
input
and
ideally
input
some
other
people
here
for
proofreading
for
for
applying
for
about
50,
k's
worth
of
consumables
and
other
stuff
for
various
labs.
Who
are
here.
That's
that's
the
idea,
so
you
know
no,
no
people
funding,
but
but
stuff
to
keep
the
lights
on.
A
It
looks
like
a
pretty
short
application,
and
so
I
think
we
should
be
able
to
put
something
in
by
the
end
of
the
month,
but
it's
the
end
of
the
month.
So
I
just
need
a
little
bit
of
bandwidth
from
everybody
to
to
maybe
help
move
that
along
more
on
that
asap.
I
was
hoping
I
was
drafted
today,
but
I've
got
roped
into
some
big
eu
proposal
the
last
few
days
and
I've
had
no
time
for
anything
else.
F
For
the
like,
so
that
has
that's
quite
short
and
probably
has
a
lot
of
cut
and
paste
stuff
in
there
right
yeah,
because
I
like
as
a
trustee,
I
can't
go
anywhere
near
the
application
right.
Okay,.
A
Right
right
input
to
it.
Okay,
great
and
you
know
what
I'd
like
to
do
is
try
and
get
some
some
funding
from
that
pot
for
everybody
who
could
use
it.
I
mean
that's
the
idea
just
to
sort
of
get
50k
of
money
for
for
helping
move
things
along.
That's
all.
F
Yeah,
let's
just
say
just
be
very,
as
you
can
say,
just
be
very
directed
in
your
application,
because
I
know
the
people
reviewing
it
they're
going
to
be
wanting
to
see
what
are
you
going
to
do
with
it
rather
than
you
know
a
loose
part
of
money
to
be
used?
I
know
what
the
chairman
will
say.
A
Okay,
great
johnny,
hanson
isn't
with
us,
but
I'll
leave
the
item
with
him.
He's
going
to
be
looking
at
some
of
the
literature
that
we've
got
to
try
to
be
more
predictive
about
the
molecules
you
might
want
to
make
peter's
with
us
work
on
crystallization
of
mercy
with
eating
compounds
and
by
joe
any
any
updates.
H
K
Great
so
we
received
the
compounds
from
lori
and
joe.
They
were
very
kind
and
they
gave
us
the
priorities,
and
so
we
have
crystallization
going
on
for
the
both
ascended
actor,
as
well
as
the
pseudomonas
mercys
and
murders.
Acinobacter
ascen
ascendiobacter
has
not
produced
any
diffracting
crystals,
but
the
pseudomonas
has
we
reproduced
our
previous
crystals.
We
got
some
little
better,
looking
ones.
Also,
you
can
see
here
they
are
kind
of
small
but
we'll
sort
of
optimize
them,
but
they're
big
enough
for
synchrotron,
and
so
we
soaked
them
with
the
compounds.
K
The
four
that
are
here.
These
are
the
priorities
that
we
received
and
then
we
got
some
crystals
from
eurod,
the
pseudomonas
one.
They
look
pretty
and
they
diffracted
about
three
angstroms
in-house
we'll
send
those
to
synchrotron.
Also,
we
couldn't
find
april
mirror
d
structure,
so
we
figured
that
may
be
of
interest,
though
also
may
be
useful
for
us
to
sort
of
just
know
how
well
the
crystals
diffract,
without
the
compounds
being
present,
so
we'll
also
take
a
crack
at
that.
K
We'll
have
some
data,
hopefully
the
22nd
is
when
we're
anticipating
it.
So
this
was
thanks
to
bart
sending
us
the
protein
and,
as
I
mentioned,
laurie
and
joe
are
sharing
the
both
the
compounds
as
well
as
the
priorities
and
then
the
smiles
and
all
the
necessary
information
that
was
important
for
us
to
log
them
and
then
get
them
into
the
pipeline.
K
My
comment
for
the
mta
that
that
bart
alluded
to
was
that
we
didn't
go
through
astrazeneca.
We
went
through
emphasis,
and
so
they
they
were
the
people
who
actually
was
important
to
them
and
that
all
of
a
sudden
made
it
important
inside.
I
think
that
both
sides
having
people
sort
of
making
it
the
priority,
makes
it
the
paperwork
go
a
lot
faster.
So
that's
my
recommendation
is
find
someone
that
cares
and
then
get
them.
Your
advocate
internally,
but.
D
K
F
D
K
That
you
know,
if
you
have
the
right
advocates
and
the
right
people
sort
of
making
the
right
phone
calls.
I
think
it's
a
lot
easier
on
both
sides
and
we
were
part
of
ssgc
at
the
time.
So
I
think
that
that's
sort
of
how
we
got
the
information
everything
sort
of
taken
care
of
we
were
small
cro,
so
our
name
of
the
game
was
to
get
you
know,
cda
put
in
place
in
a
day
or
two.
D
Great
great
great
progress,
peter
thanks,
that's
very
exciting.
You
know
just
for
the
rest
of
the
team,
and
these
are
selections-
are
kind
of
made
by
docking
they're
small,
relatively
small
kind
of
using
the
same
hinge.
Well,
sorry,
nothing
binding,
but
the
same
binding
to
asparagine
that
atp
binds
to
you
know
we
don't
have
biological
data
on
those
compounds.
So
we
don't.
You
know
this
is
a
little
bit
of
a
crap
shoot,
but
I
think
the
great
thing
is.
Hopefully
there
will
be
some
structures,
but
also
the
fact
that
peter's
got.
D
You
know
these.
You
know
crystal
systems
set
up
that
will,
hopefully
you
know
if
we
don't
have
anything.
Maybe
we
can
can
think
about
other
compounds
that
if
peter
is
still
willing
to
help
out
with
you
know,
going
down
the
road
sure.
So
it's
fantastic.
Thank
you.
So
much
really
appreciate
it.
K
Sure
thing
yeah,
just
let
me
know
what
compounds
you
want
and
then
you
know
find
funnel
into
us
through
bart
and
we'll
be
happy
to
set
them
up
the
more
now
that
we
have
the
crystal
system
set
up.
I
think
that
the
more
likely
that
they
bind
the
more
likely
we'll
get
you
information
on
them.
But
you
know
if
the
the
usual
the
magic
number
of
solubility
is
the
the
affinity.
That's
usually
is
a
lot
tougher.
K
Everything's
the
same
part,
it's
just
you
know,
everything
was.
K
When
you
were
here,
it's
just
different
branding
different
locations,
but
overall
the
same
shops
same
people
and
we
have
a
little
bit
improved
imaging.
As
you
can
tell.
K
It
is
it's
if
you
want,
we
can
measure
it
for
you,
we
can
put
it.
A
I'm
looking
at
the
the
z
codes
there,
I'm
wondering
what
the
structures
are
and
by
chance.
The
next
action
item
is
on
youtube
to
post
the
structures
of
those
compounds.
D
A
D
Go
back
to
last
last
month's!
Oh
sorry,.
K
A
Great
all
right,
fantastic
next
thing
was
crystallized
with
others
to
establish
protein
needs
and
what's
needed
for
message.
Gcid,
I'm
not
sure.
If
that,
if
that
took
place,
chris
did
it
the
we
were
going
to
get
together
to
think
about
resources.
Yeah.
F
No,
we
did
it
didn't
actually,
but
it's
great
that
there's
some
brilliant
progress
with
pseudomonas
and
hopefully
as
soon
as
a
bacter,
so
yeah,
it's
really
just
filling
up
the
matrix
as
to
what
else,
what
else
we
could
do
with
it.
As
we
start
to
make
progress,
we
just
need
to
keep
cross-checking.
Don't
we
so
I'll?
Go
back
I'll,
have
a
chat
with
laura
and
then
get
back
to
you
matt
and
reach
out
to
joe
as
well
and
anyone
else
who
feels
they
would
like
to
send
me
a
map.
I
Yeah,
that
would
be
great
we're
kind
of
short
on
in
the
sstcid
pipeline.
If
you
wanted
to
do
a
whole
bunch
mercy
d
and
e
proteins
from
different
organisms,
that
would
be
timely
for
us
to
get
done.
D
Sorry
can
I
make
a
suggestion
so
so
laura
now
now
that-
and
I
don't
know
if
peter's
up
for
this-
but
I
guess
it's
a
conversation
between
peter
and
laura,
but
you
know
we
do
have
600
compounds
sitting
from
you
mean
sitting
somewhere.
I
don't
know
if
they're
in
warwick
or
diamond,
I
guess
there
should
be
some
with
diamond
so
peter
I
don't
assume
you
don't
really
have
like
the
x-chem
facility.
You
know
you're
kind
of
doing
kind
of
comp
more.
We
call
it
cereal
or
small
parallel.
D
D
Because
it
was
done
against
mere
e,
and
I
think
we
kind
of
was
you
know,
which
is
fine.
The
original
600
x-com
screen,
but
a
lot
of
stuff
was
really
kind
of
done
against
mirror
c
in
terms
of
the
compound
selection.
D
K
K
D
K
We've
done
crystallography-based
screening,
it's
it's!
I
don't
think
that
we're
adverse
or
we're
against
doing
that.
I
think
that
we're
just
sort
of
we're
definitely
not
looking
to
screen
600
individual.
You
know
crystals
with
different
compounds,
because
I
think
that
that
would
be
just
the
time.
I'm
not
sure
if
I
would
need
ssgcid
brass
to
sort
of
approve
that
kind
of
time.
Investment,
but
overall.
K
A
Chatting
because
she
doesn't
have
a
microphone,
but
she
says
they
they're
in
an
echo
play,
so
she
can
transfer
them
easily.
G
K
F
I
suppose
the
only
other
alternative
would
be
it
to
make
to
to
make
to
make
the
crystals
that
that
fit
xk
parameters
with
resilience
to
peg
concentrations
or
dmso
concentrations
that
you
know
you
know
reliably
high
diffracting
crystals.
You
could
then
just
clone
that
protocol
and
then
just
run
it
through
a
next
can
screen
over
a
weekend.
F
G
I
So,
but
on
that
we're
we
everything
that
ssgcid
does
is
freely
available
to
the
community.
So
there's
also
the
possibility
like
we
can
just
send
you
the
plasmids.
We
can
send
you
protein
if
we
make
it
stuff
like
that,
like
we
don't
and
there
is
an
mta
involved,
but
it's
it's
a
very
basic
electronic
mta.
That
says
you
agree
to
make
all
your
results
or
you
agree
to
publish
everything
and
deposit
everything
in
the
protein
data
bank.
That's.
F
A
D
A
A
H
F
Oh,
they
love
legal
contracts.
The
welcome
do,
and
that
was
part
of
the
problem.
With
my
little
welcome
grant
for
47
years,
it
was
all
the
legals
okay
they're,
so
they
could
get
profit
out
of
it.
So
I
had
to
work
out
what
they
could
have
profit,
and
I
decided
it
was
the
assay
design
development
and
they
were
happy
with
that.
A
You
just
have
an
issue
about
the
fact
that
then
you
know
you
then
have
an
agreement
with
a
with
a
charity
organization,
open
source,
antibiotics
and
then
the
question
is
whether
any
of
us
are
employees
of
that
thing
and,
of
course
we're
not
right.
So
you've
got
this
mta
with
osa,
but
that
doesn't
actually
help
us
because
none
of
us
work
there.
A
F
D
I'm
sorry
I
was
gonna,
I'm
sorry!
I
again,
I
can't
keep.
I
can't
keep
quiet,
but
just
back
to
this
enemy
library,
600
plus
compounds
just
just
so
the
team
knows
this
was
funded
by
a
grant
that
frank
mondelf
had
and
we
spent
well.
You
know
we
spent
over
16
000
pounds
for
that
library,
so
yeah
we
should
get.
D
We
should
use
it,
and
so
we
get
some
value
out
of
that
money
that
was
spent
out
of
frank's
lab.
A
A
I
guess
when
you
were
talking
about
mixing
them,
they
made
a
lot
of
sense
in
terms
of
keeping
down
the
number
of
experiments,
but
I
guess
that's
a
little
irreversible.
Isn't
it
so,
once
you
mix
things
you're
going
to
lose
some
of
the
advantage
of
having
isolated
compounds.
Is
that
an
issue
or
can
you
just
mix
small
amounts
of
the
samples
that
we
have
joe?
Do
you
remember
how
much
you
got
of
each
compound.
A
F
Personal
views
keep
them
separate,
get
get
get
crystals
that
will
go
through
x,
game
run
through
x,
cam.
We
can
run
the
individual
ones
through
the
assays
just
just
have
to
hold
on
like
two
or
three
weeks
for
us.
D
Yeah,
I
I
agree
with
with
with
chris
I
mean
I.
I
appreciate
peter's
efforts.
You
know
the
idea
of
pooling
and
stalin,
but
I
I
mean
the
x-cam
just
has
this
amazing
technology,
and
so
I
think
that
makes
the
most
sense
to
do.
Individual
interval,
zero
compounds,
assuming
you
can
get
an
x-cam
compatible
set
of
crystals.
A
Okay,
great
just
a
couple
of
other
small
things,
so
chris
and
I
christy
and
I
had
an
initial
conversation
with
alpha
fold,
and
we
are
following
that
up
with
some
specific
suggestions
as
to
what
to
do
and
exploring
whether
they
could
help
with
the
project.
But
there's
no
commitment.
Yet
we
were
thinking
a
little
bit
about
the
idea
of
of
trying
to
get
structures
in
that
kind
of
matrix
of
all
the
mirrors
versus
you
know
the
organism
where
they
come
from
to
try
and
form.
A
You
know
plug
some
holes
there
in
the
way
that
we
were
just
talking
about
a
second
ago,
but
chris
and
I
need
to
have
a
follow-up
conversation
and
try
and
come
up
with
something
and
then
we'll
pass
it
by
the
group
just
just
to
try
and
follow
up.
A
Is
I
think
we
have
to
it
might
be
a
good
idea
just
to
pass
that
by
people
and
then
send
it
through.
I
think
we
have
to
have
a
you
know
very
small,
targeted
request
for
them
to
have
a
goat.
That
would
they'll
be
useful
to
us,
of
course.
So
we
that
that's
on
us,
I
guess
chris
the
follower
and
then
I'm
not
sure
this
is
a
really
really
an
official
action
for
you,
but
you
were
thinking
about
maybe
liaising
with
a
david
baker
lab
about
potential
similar
protein
structure.
Prediction
work.
I
I
apologize,
I
didn't
do
that.
We,
we
do
have
a
connection
that
we
run
our
structures
through
the
david
baker
lab
the
ipd
protein
prediction
or
pipeline.
I
don't
think
it's
their
latest
casp.
I
don't
think
it's
like
their
their
highest
ip
one.
Our
pipeline
is
connected
to
that.
I
we
just
need
to
sort
of
push
things
that
way,
and
I
didn't
talk
to
isabel
who's
in
charge
of
that.
So
I'll
have
to
do
that.
Okay,
but.
H
A
Yeah,
okay
and
then
the
other
thing
I
was
going
to
mention
was
chris
swain
alerted
us
to
the
call
from
the
european
lead
factory
call
for
proposals
where
we
could
ask
them
to
do
a
screen
versus
one
of
the
mer
enzymes
deadline
is
may
28th
and
we'd
have
to
fill
in
something
by
then
it
seems
like
a
like
a
win-win.
Apart
from
the
fact,
we
have
to
put
an
application,
it
seems
like
a
win-win.
Does
anyone
think
that's
not
worth
doing.
A
I
mean
that
would
be
a
big
scale
screen,
I'm
guessing
that
the
proposal
would
be
mostly
on
the
assay,
so
we
would
be
presumably
needing
to
justify
the
idea
that
they
could
run
an
essay
for
us
right.
So
it
will
be
mostly
technical
biology
in
the
proposal,
unless
I'm
misunderstanding
what
it
is
they're
doing,
but
they
will
be
running
a
screen
for
us
with
a
bunch
of
compounds
right.
H
Yeah
I
mean
it's
500
000
compounds
now.
So
it's
it's
a
fairly
simple
screen.
H
They
would
do
all
of
that
they
would
do
the
initial
screen.
They
would
then
do
the
confirmation
screen
and
if
you
have
a
orthogonal
screen
for
something
else,
they
will
run
that
as
well.
Okay,.
A
D
So
I
guess
the
big
question
here
is,
you
know:
is
protein
and
substrate
availability
right,
so
you
have
to
provide
that
I
mean
so.
This
is
all
falls
on
chris
dawson's
lab,
and
so
you
know
do
you
have
you
know
if
you
work
out
how
much
material
do
you
actually
need
from
terms
of
like
substrates,
because
I
think
I
thought
that
was
an
issue.
You
were
having
a
little
bit
of
just
generating
substrates
or
it's
just
a
matter.
You
can
do
it,
it's
just
a
matter
of.
F
F
You
know
the
reaction
doesn't
turn
over
in
the
right
direction.
That
I
mean
I
mean
historically,
we've
made.
You
know
tens
of
hundreds
of
milligrams
of
reagents
in
every
period
of
a
week
or
two
or
three
and
we've
run
a
a
we've
run,
a
60
000
compound
mere
screen
mercy
screen
with
mrct
12
years
ago.
F
So
we've
got
12
years
more
of
experience
and
we
so
we've
gone.
We've
gone,
we've
gone
through.
F
You
know
a
mere
high
throughput
screen
once
before,
with
a
kinase,
focused
library,
I
have
to
say,
got
nothing
out
of
it,
so
yeah
no
got
nothing
out
of
it.
It's
why
even
500
000
I'm
it's
what
goes
into
it
and
I
I
and
everyone
has
screened.
You
know
this
joe.
F
You
know
how
different
is
this
library
going
to
be
to
the
one
that
astrazeneca
will
have
screened?
You
know
20
years
ago
or
merc
20
years
ago
or
pfizer
20
years
ago.
I
I'm
not
sure,
and
then
the
keys,
the
keys
and
the
chemistry
isn't
it.
You
know
that
more
than
anyone.
F
K
F
For
me,
for
me,
the
the
pitch
to
to
to
europe
would
be,
you
know,
you
need
to,
you,
know,
be
rational
and
expansive.
So
just
do
what
joe
did
and
it's
you
know
designing,
not
60
compounds
600,
but
6000
or
60.
You
know
and
do
it
in
a
more
focused
manner
really.
So
it's
not
necessarily
a
two
hundred
thousand
or
three
hundred
thousand
compound
screen.
H
H
D
K
Understand,
but
I'm
just
saying
that
no
I
mean
I
understand
that,
but
I'm
just
saying
that,
like
you
know
to
me
that
would
be
sort
of
those
are
some
of
the
aspects
that
are
sort
of
key
for
the
compound
to
work,
because
you
know
these
are,
there
are
two
members
we
need
to.
You
know
be
able
to
get
through
to
get
the
compounds
to
work.
So
you
know.
D
Yeah
I
mean
the
compounds
are
going
to
change.
Some
I
mean
you're,
not
you're,
probably
not,
hitting
a
home
run
you're,
not
hitting
an
animal
or
compound
out
of
this
screen.
Most
likely,
I
mean
awesome
if
you
did,
but
it's
not
very
unlikely,
and
so
then
the
the
fact
that
you
would
actually
get,
because
eventually
you
have
to
change
the
molecule
substantially
to
get
the
potency
from
the
original
hit
and
then
you're
changing
a
whole
bunch
of
physical
chemical
properties
and
so
any
counter
screen
of
the
compounds
from
the
library.
D
K
D
A
That's
interesting
all
right,
I
mean,
of
course
you
know
we
put
the
proposal
in
and
they
consider
it
so
these
issues
might
come
up.
If,
if
the
proposal
is
seen
as
being
favorable,
it
might
then
be
refined,
I
mean,
do
you
so
christy
are
you?
Are
you
not
keen
on
this
period
or
do
you
think
there's
value.
H
Well,
I
mean
just
to
give
you
a
bit
of
background
about
half
the
library
where
com
tranches
are
50
000
compounds
which
were
donated
by
six
pharma
companies
who
formed
the
original
consortium.
The
other
half
of
the
library
is
de
novo
synthesis,
so
they
are
new
compounds
that
have
never
been
made
before.
F
Okay,
I'm
just
thinking
about
conversation
with
chris
schofield
might
be
handy,
he's
having
successfully
gone
through
that
loop
happy
to
hook
that
in
really.
D
So
chris
chris
christie
cause
we
work
with
chris
s,
so
we
have
to
call
it
chris
s
and
chris
d,
but
anyway,
chris
d.
What
about
the
the
other
binding
site
instead
of
the
atp
site,
the
peptide
glycan,
whatever
the
other
yeah
your
time,
finding
yeah?
D
So
so
I
I
is
that
something
that
your
essay
would.
Is
there
an
essay
for
that
I
mean
I'm
just
wondering
if
that
would
be
another
more
novel
or
another
option
to
consider
I'll
have
a
chat
to
adrian
to
see
how
far
he
got
on
that.
A
Okay,
all
right,
that's
great
thanks!
Everybody
thanks
chris
s
for
noticing
that
this
could
be
really
useful.
All
right!
That's
everything
I
had
did
we
not
talk
about
anything.
Anyone
want
to
raise
anything.
A
I
think
we're
all
good
yeah
action
item
on
me
for
the
elf
is
to
send
a
legal
document
to
my
legal
office.
That's
the
first
step.
F
A
Great
all
right,
okay,
fantastic
I'll
I'll,
send
through
I've,
suggested
another
catch
up,
because
there's
lots
of
grand
stuff
going
on
at
the
moment.
I'll
suggest
another
catch
up
in
on.
When
is
it
8th
of
june
tuesday
june,
nearly
a
month
away?
Assuming
that's
okay,
I'll,
send
her
an
invite
asap
very
nice
to
see
everybody
all
right
thanks
thanks.